The use of population-specific pharmacokinetic parameters and Bayesian forecasting improves dosage-regimen design.

The potential interaction between MTX and doxycycline may cause pharmacokinetic changes, and its clinical repercussions on the quality of life of the patient and associated costs should be considered.

No abstract

the incidence of ADRs preventing planned dose intensity administration has been estimated. Follow-up of nonadherence to antineoplastic chemotherapy prescriptions can be used to evaluate tolerance in the clinical setting. Continuous evaluation of security in clinical practice provides information on benefits outweighing the deleterious effects in specific patient populations where the available data are limited.